Maralixibat (Livmarli)

Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec. This review assesses maralixibat (Livmarli), 9.5 mg of maralixibat per mL, oral solution. Indication: For the treatment of cholestatic pruritus in patients with Alagille syndrome.